Yahoo
São Paulo - Delayed Quote BRL

Raia Drogasil S.A. (RADL3.SA)

14.69 -0.75 (-4.86%)
At close: November 5 at 6:05:37 PM GMT-3
RADL3.SA Q3 2026 earnings call
Replay the call for the latest insights.
Read transcript
Chart Range Bar
Loading chart for RADL3.SA
  • Previous Close 15.44
  • Open 0.00
  • Bid 14.69 x --
  • Ask 14.97 x --
  • Day's Range 0.00 - 0.00
  • 52 Week Range 0.00 - 27.42
  • Volume 0
  • Avg. Volume 12,653,709
  • Market Cap (intraday) 25.686B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 17.49
  • EPS (TTM) 0.84
  • Earnings Date Nov 3, 2026
  • Forward Dividend & Yield 0.45 (3.07%)
  • Ex-Dividend Date Oct 8, 2026
  • 1y Target Est 25.77

Raia Drogasil S.A. engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics and specialty medicines in Brazil. The company sells its products through stores, telesales, and call centers. Raia Drogasil S.A. was founded in 1905 and is headquartered in São Paulo, Brazil.

rdsaude.com.br

73,895

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/5/2026, which may include dividends or other distributions. Benchmark is IBOVESPA (^BVSP) .

YTD Return

RADL3.SA
36.40%
IBOVESPA (^BVSP)
3.14%

1-Year Return

RADL3.SA
24.16%
IBOVESPA (^BVSP)
8.41%

3-Year Return

RADL3.SA
37.61%
IBOVESPA (^BVSP)
40.65%

5-Year Return

RADL3.SA
30.20%
IBOVESPA (^BVSP)
58.54%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 11.41B
Earnings 426.87M
Profit Margin 3.74%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
2B
4B
6B
8B
10B
12B
2.0%
2.5%
3.0%
3.5%

Analyst Insights

View More

Analyst Price Targets

20.00
25.77 Average
14.69 Current
30.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    2.78%

  • Return on Assets (ttm)

    7.30%

  • Return on Equity (ttm)

    18.46%

  • Revenue (ttm)

    46.68B

  • Net Income Avi to Common (ttm)

    1.36B

  • Diluted EPS (ttm)

    0.84

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    627.2M

  • Total Debt/Equity (mrq)

    116.96%

  • Levered Free Cash Flow (ttm)

    1.36B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: